Caris Life Sciences, Inc. (CAI)
NASDAQ: CAI · Real-Time Price · USD
17.58
-0.96 (-5.18%)
At close: Nov 20, 2026, 4:00 PM EST
18.00
+0.42 (2.39%)
After-hours: Nov 20, 2026, 7:30 PM EST
Caris Life Sciences Revenue
Caris Life Sciences had revenue of $275.36M in the quarter ending September 30, 2026, with 26.99% growth. This brings the company's total for the last twelve months to $1.05B, up 61.48% year-over-year. In the year 2025, Caris Life Sciences had annual revenue of $812.03M with 96.97% growth. That makes Caris Life Sciences the 7,438th largest company in the world by revenue and 1,768th in the United States.
Revenue (ttm)
$1.05B
Revenue Growth
+61.48%
P/S Ratio
4.81
Revenue / Employee
$567,784
Employees
1,846
Market Cap
5.04B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Caris Life Sciences breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 812.03M | 399.77M | 96.97% |
| Dec 31, 2024 | 412.26M | 106.13M | 34.67% |
| Dec 31, 2023 | 306.13M | 47.64M | 18.43% |
| Dec 31, 2022 | 258.49M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
CAI News
- 11 days ago - Caris Life Sciences price target raised to $25 from $22 at Piper Sandler - TheFly
- 16 days ago - Caris Life Sciences price target raised to $36 from $28 at Citi - TheFly
- 16 days ago - Caris Life Sciences price target raised to $38 from $36 at TD Cowen - TheFly
- 17 days ago - Caris Life Sciences price target raised to $33 from $32 at Baird - TheFly
- 17 days ago - Caris Life Sciences Earnings Call Transcript: Q3 2026 - Transcripts
- 17 days ago - Caris Life Sciences Earnings release: Q3 2026 - Filings
- 17 days ago - Caris Life Sciences Quarterly report: Q3 2026 - Filings
- 17 days ago - Caris Life Sciences Slides: Q3 2026 - Filings